- Home
- JRVR vs XOMA Comparison
JRVR vs XOMA Comparison
Compare JRVR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | XOMA |
|---|---|---|
| Founded | 2002 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.2M | 471.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | JRVR | XOMA |
|---|---|---|
| Price | $6.34 | $37.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.33 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 201.7K | 126.1K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $687,614,000.00 | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | ★ $7.91 | $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $22.29 |
| 52 Week High | $7.20 | $40.74 |
Technical Indicators
Market Signals| Indicator | JRVR | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 66.95 |
| Support Level | $6.15 | $32.73 |
| Resistance Level | $6.39 | $39.89 |
| Average True Range (ATR) | 0.16 | 1.59 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 45.45 | 64.16 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.